Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Drug Addiction Pipeline Drugs Market Overview
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body, or clothes.
The Drug Addiction Drugs in Development market research report provides an overview of the Drug Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Drug Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects.
Drug Addiction Pipeline Drugs Market Targets
The targets of the drug addiction pipeline drugs market are Mu Type Opioid Receptor, Cannabinoid Receptor 1, Kappa Type Opioid Receptor, Cannabinoid Receptor 2, Nociceptin Receptor, Oxytocin Receptor, Sodium Dependent Dopamine Transporter, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Noradrenaline Transporter, and Cytochrome P450 11B1 Mitochondrial.
drug addiction pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of Drug Addiction Pipeline Drugs Market
The mechanisms of action of the drug addiction pipeline drugs market are Mu Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Antagonist, Mu Type Opioid Receptor Antagonist, Cannabinoid Receptor 1 Antagonist, Nociceptin Receptor Agonist, Oxytocin Receptor Agonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist.
drug addiction pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Drug Addiction Pipeline Drugs Market
The routes of administration in the drug addiction pipeline drugs market are oral, intravenous, subcutaneous, intramuscular, parenteral, nasal, sublingual, and transdermal.
drug addiction pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in drug addiction Pipeline Drugs Market
The molecule types in the drug addiction pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, conjugate vaccine, gene therapy, peptide, recombinant enzyme, biologic, enzyme, recombinant vector vaccine, and vaccine.
drug addiction pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key drug addiction Pipeline Drugs Market Companies
Some of the key companies in the drug addiction pipeline drugs market are Astraea Therapeutics LLC, InterveXion Therapeutics LLC, Kinoxis Therapeutics Pty Ltd, Cerevel Therapeutics Holdings Inc, Chiesi Farmaceutici SpA, Embera NeuroTherapeutics Inc, MAKScientific LLC, Adjuvance Technologies Inc, Aelis Farma SAS, and Aether Therapeutics Inc.
drug addiction pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
| Targets | Mu Type Opioid Receptor, Cannabinoid Receptor 1, Kappa Type Opioid Receptor, Cannabinoid Receptor 2, Nociceptin Receptor, Oxytocin Receptor, Sodium Dependent Dopamine Transporter, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Noradrenaline Transporter, and Cytochrome P450 11B1 Mitochondrial |
| Mechanisms of Action | Mu Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Antagonist, Mu Type Opioid Receptor Antagonist, Cannabinoid Receptor 1 Antagonist, Nociceptin Receptor Agonist, Oxytocin Receptor Agonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist |
| Routes of Administration | Oral, Intravenous, Subcutaneous, Intramuscular, Parenteral, Nasal, Sublingual, and Transdermal |
| Molecule Types | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Conjugate Vaccine, Gene Therapy, Peptide, Recombinant Enzyme, Biologic, Enzyme, Recombinant Vector Vaccine, and Vaccine |
| Key Companies | Astraea Therapeutics LLC, InterveXion Therapeutics LLC, Kinoxis Therapeutics Pty Ltd, Cerevel Therapeutics Holdings Inc, Chiesi Farmaceutici SpA, Embera NeuroTherapeutics Inc, MAKScientific LLC, Adjuvance Technologies Inc, Aelis Farma SAS, and Aether Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of drug addiction (Central Nervous System).
- Reviews of pipeline therapeutics for drug addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in drug addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of drug addiction (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for drug addiction (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for drug addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding drug addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aelis Farma SAS
Aether Therapeutics Inc
Allaysis LLC
Amygdala Neurosciences Inc
Ananda Scientific Inc
Aphios Corp
Assertio Holdings Inc
Astraea Therapeutics LLC
Better Life Pharmaceuticals Inc
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics Holdings Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Clear Scientific LLC
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Delix Therapeutics Inc
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Entheon Biomedical Corp
EryDel SpA
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Jazz Pharmaceuticals Plc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine MindMed Inc
Mydecine Innovations Group Inc
Myosin Therapeutics Inc
Naprogenix Inc
NFL Biosciences SAS
Novartis AG
Omeros Corp
Ovid Therapeutics Inc
P2D Inc
PAION AG
Proniras Corp
Protagenic Therapeutics Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Revive Therapeutics Ltd
Saniona AB
Sen-Jam Pharmaceutical LLC
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Vivozon Inc
Zelira Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the drug addiction pipeline drugs market?
The targets of the drug addiction pipeline drugs market are Mu Type Opioid Receptor, Cannabinoid Receptor 1, Kappa Type Opioid Receptor, Cannabinoid Receptor 2, Nociceptin Receptor, Oxytocin Receptor, Sodium Dependent Dopamine Transporter, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Sodium Dependent Noradrenaline Transporter, and Cytochrome P450 11B1 Mitochondrial.
-
What are the mechanisms of action of the drug addiction pipeline drugs market?
The mechanisms of action of the drug addiction pipeline drugs market are Mu Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Antagonist, Mu Type Opioid Receptor Antagonist, Cannabinoid Receptor 1 Antagonist, Nociceptin Receptor Agonist, Oxytocin Receptor Agonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist.
-
What are the routes of administration in the drug addiction pipeline drugs market?
The routes of administration in the drug addiction pipeline drugs market oral, intravenous, subcutaneous, intramuscular, parenteral, nasal, sublingual, and transdermal.
-
What are the molecule types in the drug addiction pipeline drugs market?
The molecule types in the drug addiction pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, conjugate vaccine, gene therapy, peptide, recombinant enzyme, biologic, enzyme, recombinant vector vaccine, and vaccine.
-
Which are the key companies in the drug addiction pipeline drugs market?
Some of the key companies in the drug addiction pipeline drugs market are Astraea Therapeutics LLC, InterveXion Therapeutics LLC, Kinoxis Therapeutics Pty Ltd, Cerevel Therapeutics Holdings Inc, Chiesi Farmaceutici SpA, Embera NeuroTherapeutics Inc, MAKScientific LLC, Adjuvance Technologies Inc, Aelis Farma SAS, and Aether Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Central Nervous System reports